![]() Among all the pCR patients, mucinous adenocarcinoma patients had the worst survival, with a 3-year overall survival rate of 67.5%, whereas patients with common adenocarcinoma had an overall survival rate of 93.8% ( P < 0.001). The 3-year overall survival rate was 92.4% for those with pCR and 88.2% for those without pCR. The nomogram based on multivariate logistic regression analysis showed that clinical T4 and N2 stages were the most significant independent clinical predictors for not achieving pCR, followed by mucinous adenocarcinoma and positive pre-treatment serum CEA results. The proportion of patients with pCR was 20.5% ( n = 1,342). Results: A total of 6,555 patients were included in this study. A nomogram based on the multivariate logistics regression was built with decision curve analyses to evaluate the clinical usefulness. Multivariate analysis of the association between clinicopathological characteristics and pCR was performed, and a logistic regression model was used to identify independent predictors for pCR. Non-metastatic rectal cancer patients who received radical resection after neoadjuvant chemoradiotherapy were included in this study. Methods: A retrospective review was performed using the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2013. The aim of this research was to identify variables for predicting pCR in rectal cancer patients after nCRT and to define clinical risk factors for poor outcome after pCR to nCRT and radical resection in rectal cancer patients. 3Department of Colorectal Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Chinaīackground: Patients with rectal cancer who achieve pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) may have a better prognosis and may be eligible for non-operative management.2Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Cancer Institute, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.1Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.In addition, the most relevant finding "is that 99% of the subgroup who received anti-HER2 therapy without chemotherapy have not presented a recurrence of the disease after three years of follow-up".Yinuo Tan 1,2 †, Dongliang Fu 2,3 †, Dan Li 1,2 †, Xiangxing Kong 2,3, Kai Jiang 2,3, Liubo Chen 2,3, Ying Yuan 1,2 * and Kefeng Ding 2,3 * "This study offers a potential future therapeutic option that enables a significant reduction of toxicity and an improvement in quality of life for this patient population without reducing efficacy", explains Dr. Among this latter group, 98.9% remained cancer-free after three years of follow-up from breast cancer surgery. This is especially relevant because around 30% of these patients did not receive chemotherapy without compromising patient's outcome. Overall, 95.4% of patients who followed this chemotherapy de-escalation strategy using PHERGain's adaptive design remained cancer-free after three years of follow-up from breast cancer surgery. The results of the second primary endpoint, 3-year invasive disease-free survival in all patients assigned to group B, have been presented at the 2023 American Society of Clinical Oncology (ASCO) congress. The first primary endpoint was the pCR rate in patients with PET response included in group B, whose positive results were published in 2021 in Lancet Oncology. It was sponsored by MEDSIR, a company dedicated to advancing clinical research in oncology, and led by scientific investigators Dr. PHERGain is a randomized, controlled phase 2 clinical trial that involved 356 early-stage HER2-positive breast cancer patients from 45 centers in seven European countries. Figure: PHERGain used an adaptive clinical trial design.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |